MiMedx Group (NASDAQ:MDXG) Bolsa

MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

MiMedx Group Inc

Legal

Press Releases

MIMEDX Files Patent Infringement Lawsuit Against Surgenex

MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26

Earnings

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

Health Care

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30

MIMEDX Announces First Quarter 2025 Operating and Financial Results

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

MIMEDX to Participate in Upcoming Investor Conferences

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Geron

Gyre Therapeutics

Immunome

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Replimune Group

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Cantor Fitzgerald

Craig-Hallum

HC Wainwright & Co.

Lake Street

Mizuho

Comments

MiMedx Group

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL